ArticleViruses2022
Regulatory T Cells Decreased during Recovery from Mild COVID-19.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Functional and phenotypic characterization of peripheral blood mononuclear cells from tuberculosis patients in Southern Thailand.Frontiers in immunology · 2025Article
- Identification of blood immunological biomarkers of SARS-CoV-2 infection during pandemic in Poland.Frontiers in immunology · 2025Article
- Excess of body weight is associated with accelerated T-cell senescence in hospitalized COVID-19 patients.Immunity & ageing : I & A · 2024Article
- Responses of Helper T Cell Subsets at Diagnosis and After Discharge in Patients with Non-Severe COVID-19: A Prospective Observational Study.Journal of clinical practice and research · 2024Article
- Immune-Cell-Based Therapy for COVID-19: Current Status.Viruses · 2023Review
- Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients.Viruses · 2023Article
- Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.Vaccines · 2023Review
- T Cell Response to SARS-CoV-2 Coinfection and Comorbidities.Pathogens (Basel, Switzerland) · 2023Review
- Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.Vaccines · 2023Review
- Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depending on the intensity and duration of SARS-CoV-2 infection, the host immune response plays a significant role in immunological protection. Here, we studied the regulatory T-cell (Treg) response in relation to kinetic change and cytokine production in patients with mild COVID-19. Nineteen SARS-CoV-2-positive patients were recruited, and blood was collected at four time points, i.e., seven days after admission, after discharge, and one and three months after recovery. CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.